Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:BEAM News 21 October 2025 - 13 January 2026

Beam Therapeutics stock today: BEAM edges lower premarket after FDA alignment sparks 22% rally

Beam Therapeutics stock today: BEAM edges lower premarket after FDA alignment sparks 22% rally

New York, Jan 13, 2026, 05:28 ET — Premarket Beam Therapeutics Inc (BEAM.O) slipped roughly 0.6% to $33.47 in premarket trading Tuesday, following a sharp 22.3% jump during Monday’s session. The shares climbed as high as $36.44 Monday and saw volume around 7.0 million shares. (StockAnalysis) The jump is significant as Beam aims to transform gene-editing science into a filing regulators can realistically accept. Traders tend to reward firms that present a clearer path to approval—and penalize those bogged down in lengthy, costly trials. Beam’s update arrives amid a jam-packed biotech calendar where grabbing attention is tough. A data readout
13 January 2026
·····
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

New York, Jan 9, 2026, 15:11 EST — Regular session CRISPR Therapeutics AG shares slid on Friday, bucking a firmer broader market, after a regulatory filing flagged a chief financial officer’s share sale under a pre-arranged trading plan. (Reuters) The company’s CFO, Raju Prasad, exercised stock options for 29,700 common shares and sold 29,700 shares the same day at prices around $60, a Form 4 filed on Jan. 8 showed. The filing indicated the sales were made under a Rule 10b5-1 plan, a preset trading instruction meant to limit allegations of trading on inside information. (SEC) The timing matters because
9 January 2026
········
Beam Therapeutics stock rises 5% after BofA lifts target to $45

Beam Therapeutics stock rises 5% after BofA lifts target to $45

New York, January 6, 2026, 13:08 (EST) — Regular session Beam Therapeutics (BEAM.O) shares rose about 5% to $28.24 by early afternoon on Tuesday after Bank of America raised its price target to $45 from $43 and kept a buy rating, according to a note carried by Futu News. The stock opened at $26.64, hit a session high of $30.49 and traded about 1.1 million shares. Futunn News The move mattered because traders were pushing up gene-editing stocks broadly, a space that often moves on analyst calls and conference headlines early in the year. CRISPR Therapeutics (CRSP.O) rose about 4.4%,
6 January 2026
·····
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

NEW YORK, January 1, 2026, 18:59 ET — Market closed Shares of CRISPR Therapeutics AG ended the last trading session of 2025 down 1.4% at $52.44. U.S. stock markets were closed on Thursday for New Year’s Day, according to the NYSE holiday calendar. StockAnalysis+1 The pullback matters because CRISPR heads into 2026 with its first commercial product still early in launch and with investors seeking clearer signs of demand. The stock has tended to react sharply to shifts in sentiment around gene-editing drugmakers. Traders are also looking ahead to the next set of checkpoints: read-throughs from partner Vertex Pharmaceuticals, which
2 January 2026
·······
Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Current News Stock Price and Market Activity CRSP is trading around the mid-$60s ahead of Monday’s open. By Reuters (Nov 2) it was ~$64.04 (up +4.86% on the day) Reuters. (Nasdaq closes on Oct 31 showed ~$63.99 Reuters.) Over the past month CRSP has gained roughly 17% Genengnews, boosted by recent data releases. For example, a 3-day rally in mid-Oct lifted CRSP ~5% after the SyNTase/CTX460 results were announced Genengnews. Technical indicators are mixed: the 14-day RSI is ~50 (neutral) and the MACD is slightly negative Investing. Shorter moving averages (5/10/20-day around $63–$63.8) are giving buy signals Investing, but the
2 November 2025
·······
Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics (NASDAQ: BEAM) globenewswire.com. – Price (Oct 21, 2025): ~$30 per share (about +17% recently) ts2.tech. – Sector: Biotechnology (precision gene editing) globenewswire.com. – Recent News: FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations to Beam’s lead programs (BEAM-101 for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency) globenewswire.com stocktitan.net. Early trial data for these programs have been promising. – Analyst Outlook: Consensus is “Moderate Buy” with average 1-year target ~$45–46 marketbeat.com nasdaq.com, implying roughly 70–80% upside. Beam’s stock jumped sharply after the FDA awarded priority designations to its gene-editing therapies. On Oct 20,
21 October 2025
·····

Stock Market Today

PepsiCo stock: €2.5 billion bond deal lands as investors size up the price-cut gamble

PepsiCo stock: €2.5 billion bond deal lands as investors size up the price-cut gamble

7 February 2026
New York, Feb 7, 2026, 05:42 EST — Market closed. PepsiCo (PEP.O) has priced a €2.5 billion ($2.7 billion) four-part euro bond deal, tapping Europe’s debt market days after it laid out new affordability moves in its core snacks aisle. (Source: SEC filing). The funding matters now because investors have been fixated on whether big consumer brands can protect volumes after years of price rises. For PepsiCo, the bond sale also lines up fresh money to refinance short-term borrowings while it tries to steady demand in North America. PepsiCo shares ended Friday at $170.49, up 1.77%, after a broad U.S.
Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

7 February 2026
Walmart shares rose 3.3% Friday to $131.18, up 10% since Jan. 30, as the Dow closed above 50,000 for the first time. The retailer’s market value crossed $1 trillion this week. Investors await January inflation data on Feb. 13 and Walmart’s quarterly results on Feb. 19 for signs of continued momentum.
Go toTop